| Primary | Percentage of Participants Free of Panic Attacks as Assessed by Participant Daily eDiary During the Last Two Weeks of the Maintenance Treatment Period | Numerator is the number of participants in the period who were panic free and had no fewer that 12 eDiary entries. Denominator is the number of participants in the period who were panic free and had no fewer than 12 eDiary entries in the corresponding time period plus anyone who had an eDiary entry and reported a panic attack in the corresponding time period, regardless of number of eDiary entries. | Full Analysis Set: Panic Attack Endpoints | Posted | | Count of Participants | | Participants | | Week 13-14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | Fisher Exact | | 0.7488 | The P-value is from a two-sided hypothesis test. | Difference in proportion of participants | -0.06 | | | 2-Sided | 95 | -0.33 | 0.23 | | | Difference in the proportion of participants who were panic attack-free was estimated from observed data for the last two weeks of the maintenance treatment period. | | Superiority | | |
|
| Secondary | Change From Baseline in the Panic Disorder Severity Scale (PDSS) Total Score at Week 14 | The Panic Disorder Severity Scale (PDSS) is a 7-item scale, with each item rated on a 5-point scale (0-4), allowing a total of 0-28 where higher score reflects greater disease severity. | Full Analysis Set: Expanded | Posted | | Least Squares Mean | Standard Error | units on a scale | | Week 14 (Day 98) | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Change From Baseline in Panic Attack Frequency During the Last Two Weeks of the Maintenance Treatment Period | Panic attack frequency is defined as the total number of panic attacks over each two-week interval divided by the total number of days the eDiary was completed in the same analysis period multiplied by 14. Participants with a minimum of 7 completed diary days in a two-week interval will be considered for panic attack frequency, otherwise will be considered missing. | Full Analysis Set: Panic Attack Endpoints | Posted | | Mean | Standard Deviation | number of panic attacks/14 days | | Week 13-14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Change From Baseline in the Proportion of Participants Free of Panic Attacks as Assessed by Participant Daily Diary by Two-Week Intervals | Numerator is the number of participants who were panic free and had no fewer than 12 eDiary entries in the corresponding time period. Denominator is the number of participants in the period who were panic free and had no fewer than 12 eDiary entries in the corresponding time period plus anyone who had an eDiary entry and reported a panic attack in the corresponding time period, regardless of number of eDiary entries. * Last Two Weeks of Maintenance Treatment Prior to Subject's Completion/Early Termination = Includes assessments made in the last two weeks of the Maintenance Period prior to completion/early termination for all subjects that had at least 2 weeks of data in the maintenance period, which would be Maintenance Week 11-12 for subjects who completed and earlier for subjects who terminated study participation prior to completion. | Full Analysis Set: Panic Attack Endpoints Odds ratio and confidence intervals were not estimable (NE) because the model estimates were unattainable due to sparseness of the data. | Posted | | Count of Participants | | Participants | | Baseline through Week 14 (2 Weeks Titration and 12 Weeks Maintenance Treatment) | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID |
|
| Secondary | Change From Baseline at All Time Points up to Week 14 in the PDSS Total Score | The Panic Disorder Severity Scale (PDSS) is a 7-item scale, with each item rated on a 5-point scale (0-4), allowing a total of 0-28 where higher score reflects greater disease severity. Change from baseline = value - baseline value; n = number of participants with a non-missing value; overall N = number of participants in treatment group | Full Analysis Set: Expanded | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline through Week 14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Change From Baseline in Panic Attack Frequency by Two-Week Intervals Through Week 14 | Panic attack frequency is defined as the total number of panic attacks over each two-week interval divided by the total number of days the eDiary was completed in the same analysis period multiplied by 14. Participants with a minimum of 7 completed diary days in a two-week interval will be considered for panic attack frequency, otherwise will be considered missing. Change from baseline = value - baseline value; n = number of participants with a non-missing value; overall N = number of participants in treatment group * Last Two Weeks of Maintenance Treatment Prior to Subject's Completion/Early Termination = Includes assessments made in the last two weeks of the Maintenance Period prior to completion/early termination for all subjects that had at least 2 weeks of data in the maintenance period, which would be Maintenance Week 11-12 for subjects who completed and earlier for subjects who terminated study participation prior to completion. | Full Analysis Set: Panic Attack Endpoints | Posted | | Mean | Standard Deviation | number of panic attacks/14 days | | Baseline through Week 14 (2 Weeks Titration and 12 Weeks Maintenance Treatment) | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | |
|
| Secondary | Change From Baseline at All Time Points up to Week 14 in the Clinical Global Impression-Severity of Symptoms Scale (CGI-S) Score | The Clinical Global Impression-Severity (CGI-S) scale is a single item 7-point scale, with panic order severity rated from 1 (normal) through to 7 (most severely ill). Change from baseline = value - baseline value; n = number of participants with a non-missing value; overall N = number of participants in treatment group. | Full Analysis Set: Expanded | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline through Week 14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Change From Baseline at All Time Points up to Week 14 in the Hamilton Anxiety Scale (HAM-A) Total Score | The Hamilton Anxiety Scale (HAM-A) is a 14-item scale measures severity of anxiety symptoms. Each item is scored on a scale from 0 (not present) to 4 (severe) resulting in a total score range of 0 to 56, with higher scores indicating more severe anxiety. Change from baseline = value - baseline value; n = number of participants with a non-missing value; overall N = number of participants in treatment group. | Full Analysis Set: Expanded | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline through Week 14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | A Treatment-Emergent Adverse Event (TEAE) is any event reported on the CRF that occurs on or after the initiation of IMP and through follow-up contact. | | Posted | | Count of Participants | | Participants | | From Day 1 through Week 18 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Results | 12-lead ECGs recordings were obtained after the participant had been supine and at rest for at least 3 minutes. The number of participants with significant abnormalities is reported by 'change from baseline in QT interval as corrected for heart rate by Fridericia's formula (QTcF)'. | | Posted | | Count of Participants | | Participants | | Up to Week 14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessment Values | Protocol-required safety laboratory tests were performed, including hematology, chemistry and urinalysis tests. Reported here is the number of participants with clinically significant changes in these laboratory tests. | | Posted | | Count of Participants | | Participants | | Up to Week 18 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Number of Participants With Clinically Significant Changes in Vital Sign Measurements | Vital signs were measured with the participant in a sitting/semi-recumbent position after 3 minutes rest and included temperature, systolic and diastolic blood pressure, respiratory rate, and heart rate. Reported here is the number of participants with clinically significant changes in vital sign measurements. | | Posted | | Count of Participants | | Participants | | Up to Week 14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results | A complete physical examination consisted of measurement of weight and a review of the following body systems: head, ears, eyes, nose, mouth, skin, heart, lungs, lymph nodes, and gastrointestinal, genitourinary, and musculoskeletal systems. A full neurological examination included an assessment of the participant's mental status (level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle appearance, tone, strength, and reflexes), sensation (including Romberg sign), coordination, and gait. Reported here is the number of participants with clinically significant changes in physical or neurological examination results. | | Posted | | Number | | participants | | Up to Week 14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Number of Participants With Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) | The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent). Reported here is the number of participants with changes in suicidality assessed using the C-SSRS scale. | | Posted | | Count of Participants | | Participants | | Up to Week 14 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |
| Secondary | Number of Participants With Withdrawal Symptoms Assessed Using the Penn Physician's Withdrawal Checklist (PWC) | The PWC is a 20-item scale to measure discontinuation symptoms after stopping a medication for anxiety disorders. All 20 items are rated on a 4-point numeric-rating scale ranging from 0 (not present), 1 (mild), 2 (moderate), to 3 (severe). A total score, ranging 0 to 60, was calculated in addition to the individual scores for each item. Lower scores indicate less severity in discontinuation symptoms. Reported here is the number of participants with withdrawal symptoms assessed using the PWC. | | Posted | | Count of Participants | | Participants | | Up to Week 15 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received darigabat matching placebo, orally, BID for 2 weeks during the Titration Period and thereafter for 12 weeks during the Maintenance Treatment Period. | | OG001 | Darigabat 25 mg BID | Participants received darigabat, up to a maximum dose of 12.5 mg, orally, BID, for 2 weeks during the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks during the Maintenance Treatment Period. |
| |